<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655265</url>
  </required_header>
  <id_info>
    <org_study_id>CHOL00107</org_study_id>
    <secondary_id>EudraCT 2007-000582-37</secondary_id>
    <nct_id>NCT00655265</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication</brief_title>
  <official_title>A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCentre Study of Colesevelam as Add-on Therapy in Patients With Familial Hypercholesterolaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess whether colesevelam given as third line treatment added to a&#xD;
      maximal tolerated and stable dose of a statin and ezetimibe is able to further decrease the&#xD;
      level of LDL cholesterol in a safe and efficient manner in difficult to treat Familial&#xD;
      Hypercholesterolaemia patients who are not at their target level of LDL cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative reduction in LDL cholesterol</measure>
    <time_frame>Between baseline and 6 weeks DB treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative reduction in HDL, total cholesterol, ApoA1,ApoB,ApoB/ApoA1ratio, triglycerides</measure>
    <time_frame>Between Baseline and week 6 and week 12 DB treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative reduction in LDL cholesterol</measure>
    <time_frame>Between Baseline and week 12 DB treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Colesevelam hydrochloride film-coated tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam hydrochloride film-coated tablets</intervention_name>
    <description>tablets</description>
    <arm_group_label>Colesevelam hydrochloride film-coated tablets</arm_group_label>
    <other_name>Cholestagel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a clinical diagnosis of Familial Hypercholesterolaemia defined as&#xD;
             EITHER a.Presence of a documented LDL-receptor mutation OR b. History of untreated&#xD;
             LDL-cholesterol level above the 95th percentile for sex and age in combination with&#xD;
             documentation of at least one of the following: i.Presence of typical tendon xanthomas&#xD;
             in the patient or first degree relative. ii. An LDL-cholesterol level above the 95th&#xD;
             percentile for age and sex in a first degree relative. iii. Proven coronary artery&#xD;
             disease in the patient or in a first degree relative under the age of 60.&#xD;
&#xD;
          -  Patients must have provided and undergone lifestyle changes for more than 6 months at&#xD;
             the time of Screening&#xD;
&#xD;
          -  Patients must have been treated for at least 3 consecutive months preceding the&#xD;
             Screening visit with a lipid lowering treatment regimen consisting of maximal&#xD;
             tolerated combination of a statin with ezetimibe and are still above their target for&#xD;
             LDL cholesterol being 2.5 mmol/L (100 mg/dL)&#xD;
&#xD;
          -  Patients must be committed to following the protocol requirements as evidence by&#xD;
             written informed consent&#xD;
&#xD;
          -  Patients should be comfortable with swallowing 3 placebo tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a known allergy to any of the components used in colesevelam or placebo&#xD;
             or any other medications like statin or ezetimibe required for participation in this&#xD;
             study&#xD;
&#xD;
          -  Patients with a bowel or biliary obstruction&#xD;
&#xD;
          -  Patients with secondary causes of hypercholesterolaemia, e.g., dysproteinaemia,&#xD;
             hypothyroidism, nephrotic syndrome (defined as proteinuria &gt;2 g/L), obstructive liver&#xD;
             disease, other pharmacological therapies, alcoholism&#xD;
&#xD;
          -  Patients with triglyceride level of &gt; 3.4 mmol/L&#xD;
&#xD;
          -  Patients with dysphagia, swallowing disorders, severe gastrointestinal motility&#xD;
             disorders, inflammatory bowel disease, or major gastrointestinal tract surgery&#xD;
&#xD;
          -  Patients have undergone LDL-apheresis within one year prior to the screening visit&#xD;
             and/or need to undergo LDL-apheresis&#xD;
&#xD;
          -  Patients with active liver disease or unexplained persistent elevations in&#xD;
             transaminases&#xD;
&#xD;
          -  Patients on fenofibrates or on concomitant cholestyramine as this will affect the area&#xD;
             under the curve (AUC) of ezetimibe&#xD;
&#xD;
          -  Patients with poorly-controlled diabetes (i.e., HbA1c&gt;9% at Screening)&#xD;
&#xD;
          -  Patients with clinically significant (CS) abnormal haematology, renal, or other&#xD;
             laboratory parameters that could be the result of an underlying malignancy or systemic&#xD;
             infection as judged by the investigator&#xD;
&#xD;
          -  Patients with a heart transplant, concurrent congestive heart failure (NYHA Class 3 or&#xD;
             4), life-threatening ventricular arrhythmias, unstable angina, recent myocardial&#xD;
             infarction within the past 6 months prior to screening, or patients undergoing&#xD;
             haemodialysis, or with active disease who may not be healthy enough to successfully&#xD;
             complete all protocol requirements&#xD;
&#xD;
          -  Fertile women who are pregnant, nursing or using either no or an inadequate form of&#xD;
             contraception taking into account the recommendations for adequate intake of oral&#xD;
             contraceptives as outlined in concomitant medication section&#xD;
&#xD;
          -  Patients with a recent history of alcoholism or drug abuse, or sever emotional&#xD;
             behavioural or psychiatric problems who may not be able to adequately comply with the&#xD;
             requirements of the study or who may be unable to consent&#xD;
&#xD;
          -  Patients receiving experimental medications or participating in another study using an&#xD;
             experimental drug or procedure within 30 days prior to signing informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Metabolisme Prevention des Maladies Cardio-Vasculaires</name>
      <address>
        <city>Paris Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TweeSteden Ziekenhius</name>
      <address>
        <city>Waalwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Metabolism and Endocrinology</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University of Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

